Cellosaurus logo
expasy logo

Cellosaurus MeWo (CVCL_0445)

[Text version]
Cell line name MeWo
Synonyms MEWO; Mewo; Me Wo; Me-Wo; Mevo; SK-MEL-MeWo; Mel-MeWo; BI-Mel; EST50
Accession CVCL_0445
Resource Identification Initiative To cite this cell line use: MeWo (RRID:CVCL_0445)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Population: Caucasian.
Doubling time: ~32 hours (PBCF).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: HLA class I peptidome analysis by proteomics.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
Sequence variations
  • Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Heterozygous (PubMed=9598804).
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (PubMed=9598804; PubMed=17260012; PubMed=23851445; ATCC=HTB-65; DepMap=ACH-000987).
  • Mutation; HGNC; HGNC:3688; FGFR1; Simple; p.Pro252Ser (c.754C>T); Zygosity=Unspecified (PubMed=23851445).
  • Mutation; HGNC; HGNC:6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (ATCC=HTB-65).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*02:01,26:01
HLA-BB*14:02,38:01
HLA-CC*08:02,12:03
Class II
HLA-DPDPB1*04:01,04:02
HLA-DQDQB1*03:01:01,05:01
HLA-DRDRB1*11:01,01:02

Source: PubMed=25960936
Class I
HLA-AA*02:01,26:01

Source: PubMed=26589293
Class I
HLA-AA*02:01,26:01
HLA-BB*14:02,67:02
HLA-CC*12:03,12:03
Class II
HLA-DQDQB1*06:13,06:13
HLA-DRDRB1*11:30,14:17
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.39
Native American1.31
East Asian, North0.6
East Asian, South0.77
South Asian7.24
European, North25.84
European, South61.86
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_AZ60 (MeWo CIS 0.01)CVCL_AZ74 (MeWo CIS 1)CVCL_AZ61 (MeWo ETO 0.1)
CVCL_AZ62 (MeWo ETO 1)CVCL_AZ75 (MeWo FOTE 4)CVCL_AZ76 (MeWo FOTE 40)
CVCL_Y663 (MeWo LNI 6I)CVCL_AZ63 (MeWo VIN 0.5)CVCL_AZ77 (MeWo VIN 5)
CVCL_U937 (MeWo-LC1)CVCL_J260 (MeWo-Luc)
Sex of cell Male
Age at sampling 78Y
Category Cancer cell line
STR profile Source(s): ATCC=HTB-65; CLS=300285; Cosmic-CLP=908128; ESTDAB=ESTDAB-050; JCRB=JCRB0066; PubMed=25877200; Technion Genomics Center

Markers:
AmelogeninX,Y
CSF1PO10,12 (ESTDAB=ESTDAB-050)
12 (ATCC=HTB-65; CLS=300285; Cosmic-CLP=908128; JCRB=JCRB0066; PubMed=25877200; Technion Genomics Center)
D1S165615,16
D2S44110,11
D2S133821,23
D3S135817
D5S81812,13
D7S82010,12
D8S117913,15
D10S124813
D12S39117
D13S3178 (Cosmic-CLP=908128; ESTDAB=ESTDAB-050)
8,9 (ATCC=HTB-65; CLS=300285; JCRB=JCRB0066; PubMed=25877200; Technion Genomics Center)
D16S53910,12
D18S5114,17
D19S43314,16
D21S1130,32.2
D22S104511,15
DYS39110
FGA22
Penta D10
Penta E5 (CLS=300285)
5,15 (ATCC=HTB-65; PubMed=25877200; Technion Genomics Center)
TH017,9
TPOX8,10 (ATCC=HTB-65; CLS=300285; Cosmic-CLP=908128; JCRB=JCRB0066; PubMed=25877200; Technion Genomics Center)
9,11 (ESTDAB=ESTDAB-050)
vWA15

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/#!Synapse:syn31544466
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-532.html
Publications

PubMed=978138; DOI=10.1084/jem.144.4.873; PMCID=PMC2190439
Shiku H., Takahashi T., Oettgen H.F., Old L.J.
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
J. Exp. Med. 144:873-881(1976)

PubMed=1067619; DOI=10.1073/pnas.73.9.3278; PMCID=PMC431008
Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F., Old L.J.
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

DOI=10.1007/BF00199208
Bruggen J., Sorg C., Macher E.
Membrane associated antigens of human malignant melanoma V: Serological typing of cell lines using antisera from nonhuman primates.
Cancer Immunol. Immunother. 5:53-62(1978)

PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812
Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F., Old L.J.
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980)

DOI=10.1007/978-1-4615-7228-2_39
Houghton A.N., Oettgen H.F., Old L.J.
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981)

DOI=10.1007/BF00205883
Bruggen J., Macher E., Sorg C.
Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma.
Cancer Immunol. Immunother. 10:121-127(1981)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=7175440; DOI=10.1084/jem.156.6.1755; PMCID=PMC2186870
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J. Exp. Med. 156:1755-1766(1982)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=1383272; DOI=10.1172/JCI116007; PMCID=PMC443186
Nip J., Shibata H., Loskutoff D.J., Cheresh D.A., Brodt P.
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.
J. Clin. Invest. 90:1406-1413(1992)

PubMed=7908310; DOI=10.1080/09553009414550371
Muller W.-U., Bauch T., Streffer C., Niedereichholz F., Bocker W.
Comet assay studies of radiation-induced DNA damage and repair in various tumour cell lines.
Int. J. Radiat. Biol. 65:315-319(1994)

PubMed=7646526; DOI=10.1006/bbrc.1995.2187
Artuc M., Nurnberg W., Czarnetzki B.M., Schadendorf D.
Characterization of gene regulatory elements for selective gene expression in human melanoma cells.
Biochem. Biophys. Res. Commun. 213:699-705(1995)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A., Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=17260012; DOI=10.1038/sj.onc.1210252
Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 26:4738-4748(2007)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27600516; DOI=10.1007/s00262-016-1897-3; PMCID=PMC5509013
Gloger A., Ritz D., Fugmann T., Neri D.
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Cancer Immunol. Immunother. 65:1377-1393(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; HTB-65
BCRC; 60540
BCRJ; 0358
CLS; 300285
ECACC; 93082609
ICLC; HTL97019
JCRB; JCRB0066
Cell line databases/resources CLO; CLO_0007687
CLO; CLO_0007688
MCCL; MCC:0000341
CLDB; cl3456
CLDB; cl3458
cancercelllines; CVCL_0445
Cell_Model_Passport; SIDM00545
Cosmic-CLP; 908128
DepMap; ACH-000987
ESTDAB; ESTDAB-050
LINCS_LDP; LCL-1253
Lonza; 437
Anatomy/cell type resources BTO; BTO_0003301
Biological sample resources BioSample; SAMN01821578
BioSample; SAMN01821699
BioSample; SAMN03470821
BioSample; SAMN05292463
BioSample; SAMN10987991
CRISP screens repositories BioGRID_ORCS_Cell_line; 184
Chemistry resources ChEMBL-Cells; CHEMBL3308024
ChEMBL-Targets; CHEMBL613300
GDSC; 908128
PharmacoDB; Mewo_918_2019
PubChem_Cell_line; CVCL_0445
Encyclopedic resources Wikidata; Q54905336
Experimental variables resources EFO; EFO_0006648
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM156016
GEO; GSM188224
GEO; GSM188254
GEO; GSM188313
GEO; GSM206525
GEO; GSM274688
GEO; GSM827470
GEO; GSM887310
GEO; GSM888386
GEO; GSM1670097
GEO; GSM3039511
GEO; GSM3039514
GEO; GSM3039515
Polymorphism and mutation databases Cosmic; 721835
Cosmic; 886829
Cosmic; 908128
Cosmic; 928689
Cosmic; 932713
Cosmic; 933141
Cosmic; 972284
Cosmic; 1047647
Cosmic; 1060422
Cosmic; 1132584
Cosmic; 1238113
Cosmic; 1303046
Cosmic; 1995506
Cosmic; 2036702
Cosmic; 2159442
Cosmic; 2163794
Cosmic; 2651875
IARC_TP53; 26074
LiGeA; CCLE_829
Progenetix; CVCL_0445
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number47